Dennis J. Slamon, MD, PhD
The discovery of the estrogen receptor in the mid-twentieth century by Elwood V. Jensen, PhD, marked a new era of treatment for patients with hormone receptor (HR)-positive breast cancer. As researchers continue to learn how to best target the estrogen receptor, new treatments are emerging in this landscape.
Clinical studies of the hormonal therapy fulvestrant (Faslodex) offered the first glimmer of hope that something other than chemotherapy could induce durable, lasting responses in these patients, said Hurvitz. Since then, fulvestrant has become a staple in the treatment of postmenopausal patients with HR-positive breast cancer.
The Introduction of CDK4/6 Inhibitors
For HR-positive patients with estrogen receptor (ER)-positive breast cancer, CDK4/6 inhibitors have emerged as a very potent therapy. Slamon, the director of Clinical/Translational Research, Revlon/UCLA Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, said that this was based on a breakthrough therapy that almost did not happen.
... to read the full story